<DOC>
	<DOC>NCT00140894</DOC>
	<brief_summary>A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.</brief_summary>
	<brief_title>A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<criteria>Males or females at least 18 years of age with familial adenomatous polyposis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Cancer Pain</keyword>
</DOC>